Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Merck says it reviewed initial data from three late-stage clinical trials and did not find evidence preladenant was more effective than a placebo.
The company says it doesn't plan to file for marketing approval of the drug. It says the decision was not related to any safety problems.
Shares of Merck rose 62 cents to $47.33 on Thursday. The stock lost 21 cents to $47.12 in after-hours trading.
© 2013 The Associated Press. All rights reserved.
Citation:
Merck ends development of Parkinson's disease drug (2013, May 23)
retrieved 19 April 2024
from https://medicalxpress.com/news/2013-05-merck-parkinson-disease-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
